Climb Biotherapeutics, Inc. Financials
CLYM
All currency values in $ millions unless otherwise noted
Scroll
| Income Statement | DEC 2025 ~1.4:1 split | DEC 2024 ~1.8:1 split | DEC 2023 | DEC 2022 2:1 split | DEC 2021 ~5.6:1 split |
|---|---|---|---|---|---|
| General & Administrative | $21 | $16 | $25 | $19 | $12 |
| Research & Development | $47 | $14 | $15 | $26 | $23 |
| Other Operating Expenses | – | – | – | $1 | $0 |
| Total Operating Expenses | $68 | $82 | $40 | $45 | $36 |
| Operating Income | -$68 | -$82 | -$40 | -$45 | -$36 |
| Non-Operating | |||||
| Net Interest Expense | $8 | $8 | – | – | – |
| Other Non-Operating Income (Expense) | $8 | $8 | $5 | -$1 | -$12 |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | |||||
| Net Income | -$60 | -$74 | -$35 | -$45 | -$47 |
| EPS (Basic) | -$0.88 | -$1.53 | -$1.30 | -$1.72 | -$4.24 |
| EPS (Diluted) | -$0.88 | -$1.53 | -$1.30 | -$1.72 | -$4.24 |
| Weighted Avg Shares (Basic) | 67.8M | 48.2M | 27.0M | 26.3M | 12.3M |
| Weighted Avg Shares (Diluted) | 67.8M | 48.2M | 27.0M | 26.3M | 12.3M |
| Shares Outstanding | 67.8M | 48.2M | 27.0M | 26.3M | 12.3M |
Climb Biotherapeutics (CLYM) financials: revenue, profit and margins
Climb Biotherapeutics (CLYM) generated about n/a in revenue and -$59 million in net income over the trailing twelve months. Figures are from SEC filings; this is analysis, not investment advice.
Frequently asked
Is Climb Biotherapeutics profitable?+
Climb Biotherapeutics reported about -$59 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
SourceFinancial statements computed from the 10-Q filed 30 Oct 2026, covering the period ending 30 Sept 2026, as reported to the SEC. Data last refreshed 11 Nov 2026. How this is calculated.
Fiscal year ends Dec.
Peers
Pharmaceutical Preparations · Pick stocks to compare with CLYM
Held by ETFs
CLYM is in 15 US ETFs. The largest of them, with CLYM's weight in each:
iShares Russell 2000 Growth ETFIWO0.01%of the fund
State Street SPDR S&P Biotech ETFXBI0.11%of the fund
Vanguard U.S. Momentum Factor ETFVFMO0.12%of the fund
Vanguard Russell 2000 Growth ETFVTWG0.01%of the fund
iShares Micro-Cap ETFIWC0.09%of the fund
Fidelity Fundamental Small-Mid Cap ETFFFSM0.11%of the fund
Spot a number that looks wrong? Check it in CLYM's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing CLYM
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.